The N-methyl-d-aspartate glutamate receptor (NMDAR) has been implicated in preterm brain injury (periventricular leukomalacia (PVL)) and represents a potential therapeutic target. However, the antagonist dizocilpine (MK-801) has been reported to increase constitutive neuronal apoptosis in the developing rat brain, limiting its clinical use in the developing brain. Memantine is another use-dependent NMDAR antagonist with shorter binding kinetics and has been demonstrated to be protective in a rat model of PVL, without effects on normal myelination or cortical growth. To further evaluate the safety of memantine in the developing brain, we demonstrate here that, in contrast to MK-801, memantine at neuroprotective doses does not increase neuronal constitutive apoptosis. In addition, there are no long-term alterations in the expression of NMDAR subunits, AMPAR subunits, and two markers of synaptogenesis, Synapsin-1 and PSD95. Evaluating clinically approved drugs in preclinical neonatal animal models of early brain development is an important prerequisite to considering them for clinical trial in preterm infants and early childhood.
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Introduction
Memantine is an uncompetitive N-methyl-d-aspartate glutamate receptor (NMDAR) antagonist (Bormann, 1989) , approved for clinical use in moderate to severe Alzheimer's disease (Forest Pharmaceuticals Inc, 2003) . It is similar to dizocilpine (MK-801) but with faster on-off kinetics (Chen et al., 1998; Lipton, 2007) as well as strong voltage and use-dependency (Parsons et al., 1995) . Currently memantine is also being studied for efficacy in children with pervasive developmental disorder (PDD) (Owley et al., 2006; Chez et al., 2007) . We have reported in a hypoxia-ischemia rat model of preterm brain injury (periventricular leukomalacia (PVL)) (Follett et al., 2000) , that memantine attenuates both the myelination deficit and cortical loss (Manning et al., 2008) , pathologies characteristic of human PVL (Volpe, 2009). However, many NMDAR antagonists including the anesthetic agents ketamine, and isoflurane, have been reported to cause a significant increase in neuronal constitutive apoptosis in immature rodents (Young et al., 2005; Johnson et al., 2008) , and more recently in non-human primates * Corresponding author at: Professor of Neurology, Children's Hospital Boston, CLS 14073, 300 Longwood Avenue, Boston, MA 02115, USA, Tel.: +1 617 919 2445; fax: +1 617 919 2769.
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during early postnatal brain growth (Zou et al., 2009; Brambrink et al., 2010) . NMDAR blockade in the immature brain may also affect plasticity. For example, NMDAR signaling regulates NMDAR subunit expression (Wilson et al., 1998) , and AMPAR incorporation at developing synapses (Shi et al., 1999; Hall et al., 2007; Wang and Kriegstein, 2008) . The period of neuronal constitutive apoptosis also coincides with rapid brain growth and synaptogenesis. Because memantine is clinically available, safe in adults ( Thomas and Grossberg, 2009) , and has a demonstrated target in the brain of preterm infants (Manning et al., 2008) , we decided to investigate its safety profile in normal developing rat pups. Previously we reported that memantine did not alter gross myelination or cortical growth in uninjured immature rats (Manning et al., 2008 ). Here we compare memantine's effects on constitutive apoptosis to those of MK-801. Additionally, we evaluate short and longer-term effects of memantine on markers of synapse development in the immature rat brain, including NMDAR subunits, AMPAR subunits, Synapsin-1, and PSD95.
